SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Raptor Pharmaceutical Corporation – RPTP

NEW YORK, NY / ACCESSWIRE / September 14, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Raptor Pharmaceutical Corporation (“Raptor” or the “Company”) (NASDAQ: RPTP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Raptor and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 14, 2015, pre-market, the Company reported that RP103, its product candidate for treatment of nonalcoholic steatohepatitis (NASH) in adolescents, failed to achieve its primary endpoint in a Phase IIb study. Based on the results, the Company will cease development of RP103 for NASH.

On this news, the Company’s stock has fallen as much as $4.64, or 38.6%, during intraday trading on September 14, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 431956